Ruchita Sinha

Ruchita leads healthcare investing at AV8 and has spent her professional career in the healthcare industry as a scientist, operator, investor and advisor to healthcare and life science startups.

Prior to AV8, Ruchita was the head of digital health investing at Sanofi Ventures where she created the strategy and built a portfolio of investments including Inozyme, (NASDAQ: INZY), Omada Health, Evidation Health, Curisium (Acq. Health Verity), Click Therapeutics, Aetion, Science 37 and Common Sensing. Earlier, Ruchita was at GE Ventures, where she led a range of initiatives including equity investments, partnerships, and portfolio management. She executed deals that delivered millions in upside for GE Healthcare businesses.

Ruchita started her career as a scientist at Maxygen and also spent time at Pfizer’s Strategy & BD group and as a management consultant with LEK Consulting. She was nominated to the Global Corporate Venturing Forum Powerlist in 2018 and 2019 and also serves on the advisory board of the BIO Investor Forum.

She holds an MBA from the University of Chicago, MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and BS in Biochemistry from Mount Holyoke College.